SEC Form 4 · accession 0001179110-17-013850
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan D Maynard
Officer — EVP & CFO
Period of report
Nov 3, 2017
Accepted (ET)
Nov 7, 2017 · 9:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 3, 2017 | M | 100,000 | $2.14 | A | 100,000 | D | |
| Common StockF1 | Nov 3, 2017 | S | 100,000 | $3.90 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $2.14 | Nov 3, 2017 | M | 100,000 | D | — | Jan 26, 2025 | Common Stock | 100,000 | 75,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017.
- F2The option vested monthly over two years from January 1, 2015.